Literature DB >> 16825812

Evaluation of p53 nuclear accumulation in low- and high-grade (WHO/ISUP classification) transitional papillary carcinomas of the bladder for tumor recurrence and progression.

Enver Vardar1, Bulent Gunlusoy, Süleyman Minareci, Hakan Postaci, Ali Riza Ayder.   

Abstract

OBJECTIVES: To evaluate the association of p53 nuclear accumulation with recurrence and progression in transitional cell carcinomas of the bladder and to examine the distribution of p53 in low-grade and high-grade transitional cell carcinomas according to the World Health Organization/International Society of Urological Pathology classification. PATIENTS AND METHODS: Nuclear accumulations of p53 were examined in a total of 99 patients with transitional cell carcinoma between May 1995 and October 1999. The mean age was 64 years. There were 94 (95%) men and 5 (5%) women. Following resection, surgical specimens were examined, and p53 accumulation with a 20% cutoff value was accepted as positive staining. Of the 99 patients, 52 (53%) had histologically superficial bladder tumors, and 47 (47%) had invasive tumors. Data concerning grade, stage, number of recurrences, and disease progression were available for each patient.
RESULTS: The median follow-up period was 55 months. 60 of the 99 patients (61%) had p53 overexpression. The difference for p53 overexpression between low-grade and high-grade tumors was significant (p < 0.05). In low- and high-grade tumors, there was no significant relationship for recurrence between p53-positive and p53-negative groups. But there was a statistically significant relationship between progression and histological grade of the tumors. p53 had no significant relationship with tumor recurrences (p > 0.05), but its relationship with progression was statistically significant (p < 0.05).
CONCLUSIONS: We did not find a correlation between tumor recurrence and p53 overexpression, but p53 overexpression has a predictive value in determining tumor progression. High-grade tumors had higher p53-positive values than low-grade tumors. This group of patients should be considered for radical therapies on the basis of other prognostic parameters.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16825812     DOI: 10.1159/000092931

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  2 in total

1.  The Potential Value of EGFR and P53 Immunostaining in Tumors of the Urinary Bladder.

Authors:  N Ibrahim; A Elzagheid; H El-Hashmi; K Syrjänen; S Alhakim
Journal:  Libyan J Med       Date:  2009-12-01       Impact factor: 1.657

2.  P53 and cancer-associated sialylated glycans are surrogate markers of cancerization of the bladder associated with Schistosoma haematobium infection.

Authors:  Júlio Santos; Elisabete Fernandes; José Alexandre Ferreira; Luís Lima; Ana Tavares; Andreia Peixoto; Beatriz Parreira; José Manuel Correia da Costa; Paul J Brindley; Carlos Lopes; Lúcio L Santos
Journal:  PLoS Negl Trop Dis       Date:  2014-12-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.